News
AgNovos Bioscience Announces 150th Patient Enrolled in RESTORE
AgNovos Bioscience announces that more than 150 patients have been enrolled in the RESTORE randomized, controlled trial of AGN1 LOEP.
News & Events
Keep up to date on AgNovos events and related news
Featured posts
All Articles
AgNovos Healthcare at Osteologie Kongress Salzburg in March 2020
AgNovos Healthcare will participate in the “Osteologie Kongress” in Salzburg from March 12th - 14th.
AgNovos Healthcare at WCO in Barcelona from April 2nd – 5th, 2020
AgNovos Healthcare will participate in the WCO in Barcelona from April 2nd – 5th, 2020.
AgNovos Healthcare at 5th Alterstraumatologie Kongress Munich 2020
AgNovos Healthcare will participate in the “Alterstraumatologie Kongress” in Munich from March 19th - 20th where we will exhibit the CE-marked OSSURE LOEP kit.
AgNovos Healthcare receives ethics committee approvals for the RESTORE study in Netherlands and Austria
The study titled Randomized Controlled Study of a Local Osteo-Enhancement Procedure (LOEP) to Prevent Secondary Hip Fractures in Osteoporotic Women Undergoing Treatment of Index Hip Fractures (RESTORE) is a randomized, controlled, prospective, single blinded, multi-national study.
AgNovos Healthcare at DKOU in Berlin from October 22nd - 25th, 2019
AgNovos Healthcare will participate at DKOU in Berlin from October 22nd to 25th, 2019.
New treatment methods for local osteoporotic bone loss - NDR Broadcast with Dr. Müller
The German broadcast channel NDR published a television report about new treatment methods for local osteoporotic bone loss.